bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: M A M F J
2017: D N O S A J J M

 
  Other news for:
Colonic Neoplasms
Pancreatic Neoplasms
Rectal Neoplasms
 Resources from HONselect
Lutathera Approved for Some Gastro and Pancreatic Cancers

By Scott Roberts

FRIDAY, Jan. 26, 2018 (HealthDay News) -- Lutathera (lutetium Lu 177 dotatate) is the first radioactive drug to be approved by the U.S. Food and Drug Administration to treat certain cancers of the gastrointestinal tract and pancreas, the agency said Friday in a news release.

About 1 in 27,000 people is diagnosed annually with this type of cancer, called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In addition to the pancreas, the cancer also may emerge in the stomach, intestines, colon and rectum, the FDA said.

"GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.

Lutathera is designed to bind to these cancer cells, allowing the radiation to target the tumors, the agency said.

The drug was evaluated in two clinical studies involving more than 1,400 people. Survival with no signs of disease progression was longer for participants who received the drug than among those who didn't.

Lutathera's most common side effects included low levels of white blood cells, high enzyme levels, vomiting, nausea, high blood sugar and low blood potassium. More serious adverse reactions could include low blood-cell levels, certain blood or bone marrow cancers, kidney or liver damage, and infertility, the FDA said.

The drug is produced by the French firm Advanced Accelerator Applications.

More information

Visit the American Cancer Society to learn more.

SOURCE: Jan. 26, 2018 press release, U.S. Food and Drug Administration

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=730558

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Pancreatic Neoplasms
Blood
Pancreas
Bone Marrow
Cells
Disease Progression
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact